Form 4: aTyr Pharma Director John K. Clarke Acquires 24,000 Stock Options

Director John K. Clarke acquired 24,000 stock options in aTyr Pharma, Inc. on May 22, 2024.

Summary

• On May 22, 2024, John K. Clarke, a director of aTyr Pharma, Inc., acquired 24,000 stock options.
• The options have an exercise price of $1.86.
• These options were granted pursuant to the Issuer's non-employee director compensation policy.
• The options vest fully on the earlier of May 22, 2025, or the Issuer's 2025 Annual Meeting of Stockholders, contingent upon Clarke's continued service on the Board of Directors.
• Following the transaction, Clarke directly owns 24,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock option grants. It doesn't contain overtly positive or negative information, hence a neutral sentiment score.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing shareholder value.

Key Dates